After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing ...

After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...

In Alzheimer’s disease (AD), significant numbers of nerve cells in the brain die, affecting patients’ ability to remember things and to think clearly — resulting in confusion, behavioral changes and ...

The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...

There is no cure for Alzheimer’s Disease (AD), but some medications may help reduce the symptoms or slow progression of the disease. As AD progresses, brain cells die and the connections between them ...

September is World Alzheimer's Month and this year’s theme is “Time to act on dementia, time to act on Alzheimer’s." ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

Namzaric (donepezil and memantine), also known as MDX-8704, ADS-8704, and Arimenda, is an approved therapy for moderate to severe Alzheimer’s disease. Allergan markets the treatment in the U.S. and ...

A reader's comment prompts columnist Ray Burow to reinforce the purpose of her column: providing hope to those with an Alzheimer's diagnosis.

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by declining mental abilities that affect a person’s memory, cognition, and personality. It is the most common cause of ...